Uncovering the facts, Holding government accountable.
Published:February 2, 2022
FOIA to FDA for Analyses or Assessments Used by FDA During Deliberations Over Aduhelm
FOIA request to the U.S. Food and Drug Administration seeking any final analyses or assessments used by FDA during deliberations over the approval of Aduhelm (aducanumab), an AlzheimerÕs drug produced by Biogen. HHS-FDA-22-0117
Select a tag below to see a full list of related documents